Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET Company Representatives Kirk Huntsman - Chairman, Chief Executive Officer Brad Amman - Chief Financial Officer Julie Gannon - Investor Relations Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Scott Henry - ROTH Capital Steve Kruger - Foresight Investing Operator Good day, everyone and welcome to the Vivos Therapeutics Incorporated First Quarter 2022 Earnings Call. At this time all pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-3224056 | | --- | --- | | ...

Start Time: 17:00 January 1, 0000 5:48 PM ET Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2021 Earnings Conference Call March 31, 2022, 17:00 PM ET Company Participants Kirk Huntsman - Chairman and CEO Brad Amman - CFO Julie Gannon - IRO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Operator Good day, everyone, and welcome to the Vivos Therapeutics Fourth Quarter and Full Year 2021 Earnings Conference Call. At this time, participants are in a listen-only mode. A question-and-answer se ...

For the Transition Period from to Commission File Number: 001-39796 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-3224056 | | --- | --- | | (State ...

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2021 Results Conference Call November 15, 2021 5:00 PM ET Company Participants Edward Loew - IR Kirk Huntsman - CEO Brad Amman - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Scott Henry - ROTH Capital Operator Good day, everyone, and welcome to the Vivos Therapeutics Inc. Third Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow management's remarks. This conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3224056 (State or other j ...

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2021 Earnings Conference Call August 12, 2021 5:00 PM ET Company Participants Edward Loew - Investor Relations Officer Kirk Huntsman - Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Scott Henry - ROTH Capital Operator Good day everyone, and welcome to the Vivos Therapeutics Second Quarter 2021 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3224056 (State or other jurisd ...

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2021 Earnings Conference Call May 17, 2021 5:00 PM ET Company Participants Edward Loew - IR Kirk Huntsman - CEO Brad Amman - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Scott Henry - ROTH Capital Operator Good afternoon, and welcome to the Vivos Therapeutics, Inc. Second (sic) [First] Quarter 2021 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Edward ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Delaware 81-3224056 (State or other j ...